Alamos Gold Helps to Create Inaugural Research Chair to Better Detect and Treat Gastrointestinal Cancers
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) has announced a $2 million contribution over ten years to The Princess Margaret Cancer Foundation to create the new Alamos Gold Chair in Gastrointestinal Surgical Oncology. Dr. Catherine O'Brien was named the inaugural Chair, effective August 1, 2024, for an initial five-year term. The funding aims to support advanced research in gastrointestinal cancers, focusing on improving early detection, developing more effective treatments, and ultimately saving lives.
Gastrointestinal cancers, affecting the stomach, liver, pancreas, colorectal region, esophagus, and small intestine, pose a significant health challenge in Canada. Over 30,000 Canadians are diagnosed with these cancers annually, with colorectal cancer accounting for approximately 26,000 cases. The research initiatives supported by this funding will include clinical trials, biomarker discovery, and studies into genetic and environmental factors contributing to gastrointestinal cancers.
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) ha annunciato un contributo di 2 milioni di dollari nell'arco di dieci anni alla Princess Margaret Cancer Foundation per creare la nuova Cattedra Alamos Gold in Oncologia Chirurgica Gastrointestinale. La Dott.ssa Catherine O'Brien è stata nominata la prima titolare della cattedra, a partire dal 1° agosto 2024, per un incarico iniziale di cinque anni. Il finanziamento ha l'obiettivo di sostenere la ricerca avanzata sui tumori gastrointestinali, con un focus sul miglioramento della diagnosi precoce, lo sviluppo di trattamenti più efficaci e, in ultima analisi, il salvataggio di vite umane.
I tumori gastrointestinali, che colpiscono lo stomaco, il fegato, il pancreas, la regione colorettale, l'esofago e l'intestino tenue, rappresentano una sfida significativa per la salute in Canada. Ogni anno, oltre 30.000 canadesi ricevono una diagnosi di questi tumori, con il cancro colorettale che rappresenta circa 26.000 casi. Le iniziative di ricerca sostenute da questo finanziamento includeranno studi clinici, scoperta di biomarcatori e ricerche sui fattori genetici e ambientali che contribuiscono ai tumori gastrointestinali.
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) ha anunciado una contribución de 2 millones de dólares a lo largo de diez años a la Princess Margaret Cancer Foundation para crear la nueva Cátedra Alamos Gold en Oncología Quirúrgica Gastrointestinal. La Dra. Catherine O'Brien fue nombrada la primera titular de la cátedra, con efecto a partir del 1 de agosto de 2024, por un período inicial de cinco años. La financiación tiene como objetivo apoyar la investigación avanzada sobre cánceres gastrointestinales, enfocándose en mejorar la detección temprana, desarrollar tratamientos más efectivos y, en última instancia, salvar vidas.
Los cánceres gastrointestinales, que afectan el estómago, el hígado, el páncreas, la región colorrectal, el esófago y el intestino delgado, representan un desafío significativo para la salud en Canadá. Más de 30,000 canadienses son diagnosticados con estos cánceres anualmente, siendo el cáncer colorrectal responsable de aproximadamente 26,000 casos. Las iniciativas de investigación apoyadas por este financiamiento incluirán ensayos clínicos, descubrimiento de biomarcadores y estudios sobre factores genéticos y ambientales que contribuyen a los cánceres gastrointestinales.
알라모스 골드 주식회사 (TSX:AGI; NYSE:AGI)는 200만 달러의 기부금을 10년에 걸쳐 프린세스 마거릿 암 재단에 기부하여 새로운 알라모스 골드 위장 암 수술학 의자를 설립한다고 발표했습니다. 캐서린 오브라이언 박사는 2024년 8월 1일부터 5년 임기의 첫 번째 의장으로 임명되었습니다. 이 기금은 위장암에 대한 선진 연구를 지원하려는 목적을 가지고 있으며, 조기 발견 개선, 보다 효과적인 치료법 개발 및 궁극적인 생명 구제에 초점을 맞추고 있습니다.
위장암은 위, 간, 췌장, 대장, 식도, 소장을 포함하여 캐나다의 건강에 중요한 도전 과제가 되고 있습니다. 매년 30,000명 이상의 캐나다인이 이러한 암 진단을 받고 있으며, 대장암이 약 26,000건을 차지하고 있습니다. 이 기금으로 지원되는 연구 이니셔티브에는 임상 시험, 바이오마커 발견, 위장암에 기여하는 유전적 및 환경적 요인 연구가 포함됩니다.
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) a annoncé un don de 2 millions de dollars sur dix ans à la Princess Margaret Cancer Foundation pour créer la nouvelle Chaire Alamos Gold en Oncologie Chirurgicale Gastro-Intestinale. Le Dr Catherine O'Brien a été nommée première titulaire de la chaire, à compter du 1er août 2024, pour un mandat initial de cinq ans. Le financement vise à soutenir la recherche avancée sur les cancers gastro-intestinaux, en mettant l'accent sur l'amélioration du dépistage précoce, le développement de traitements plus efficaces et, en fin de compte, le sauvetage de vies.
Les cancers gastro-intestinaux, touchant l'estomac, le foie, le pancréas, la région colorectale, l'œsophage et l'intestin grêle, constituent un défi de santé majeur au Canada. Chaque année, plus de 30 000 Canadiens sont diagnostiqués avec ces cancers, le cancer colorectal représentant environ 26 000 cas. Les initiatives de recherche soutenues par ce financement comprendront des essais cliniques, la découverte de biomarqueurs et des études sur les facteurs génétiques et environnementaux contribuant aux cancers gastro-intestinaux.
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) hat einen Beitrag von 2 Millionen Dollar über einen Zeitraum von zehn Jahren an die Princess Margaret Cancer Foundation angekündigt, um die neue Alamos Gold Professur für Gastrointestinale Chirurgie und Onkologie zu schaffen. Dr. Catherine O'Brien wurde zur ersten Inhaberin der Professur ernannt, die am 1. August 2024 für eine anfängliche Dauer von fünf Jahren tätig sein wird. Die Finanzierung zielt darauf ab, fortgeschrittene Forschung im Bereich der gastrointestinalen Krebserkrankungen zu unterstützen, mit dem Fokus auf die Verbesserung der Frühdiagnose, die Entwicklung effektiverer Behandlungen und letztendlich das Retten von Leben.
Gastrointestinale Krebserkrankungen, die Magen, Leber, Bauchspeicheldrüse, den Dickdarm, die Speiseröhre und den Dünndarm betreffen, stellen eine bedeutende Gesundheitsherausforderung in Kanada dar. Jährlich erhalten über 30.000 Kanadier eine Diagnose dieser Krebserkrankungen, wobei der kolorektale Krebs etwa 26.000 Fälle ausmacht. Die durch diese Finanzierung unterstützten Forschungsinitiativen umfassen klinische Studien, die Entdeckung von Biomarkern und Studien zu genetischen und umweltbedingten Faktoren, die zu gastrointestinalen Krebserkrankungen beitragen.
- Alamos Gold contributes $2 million over ten years to cancer research
- Creation of a new Research Chair in Gastrointestinal Surgical Oncology
- Potential for improved early detection and more effective treatments for gastrointestinal cancers
- None.
Insights
This $2 million contribution from Alamos Gold to establish the Gastrointestinal Surgical Oncology Chair is a significant step in advancing research for a group of cancers that collectively pose a major health challenge. With over 30,000 Canadians diagnosed annually with gastrointestinal cancers, this funding could potentially accelerate breakthroughs in early detection and treatment.
Dr. Catherine O'Brien's appointment as the inaugural Chair is promising. Her research will likely focus on critical areas such as biomarker discovery and genetic factors contributing to these cancers. This could lead to more personalized treatment approaches, potentially improving patient outcomes. However, it's important to note that translating research findings into clinical practice often takes years, so immediate impact may be
While this philanthropic initiative demonstrates Alamos Gold's commitment to corporate social responsibility, its direct financial impact on the company is likely minimal. The
However, this move could potentially enhance the company's reputation and stakeholder relations, which might indirectly benefit its social license to operate in various communities. From an investor's perspective, while commendable, such initiatives typically don't significantly influence stock performance unless they're part of a broader pattern of strong ESG practices that could attract socially conscious investors or mitigate regulatory risks.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) is proud to announce a significant contribution to The Princess Margaret Cancer Foundation to create the new Alamos Gold Chair in Gastrointestinal Surgical Oncology. The Company’s
Last month, Dr. Catherine O’Brien was named the inaugural Alamos Gold Chair in Gastrointestinal Surgical Oncology by Princess Margaret Cancer Centre at University Health Network, University of Toronto. The appointment is for an initial five-year term, effective August 1, 2024.
"This funding represents a significant step forward in the research of gastrointestinal cancers," said President & CEO John McCluskey. "By supporting advanced research, the new Chair will aim to improve early detection, develop more effective treatments, and ultimately save lives. This investment will enable researchers to explore new avenues and make breakthroughs that can transform the outlook for those affected by these cancers."
Gastrointestinal cancers encompass a variety of cancers affecting the digestive system. Specifically, this funding will focus on cancers of the stomach, liver, pancreas, colorectal region, esophagus, and small intestine. These cancers collectively pose a significant health challenge, accounting for a substantial proportion of cancer diagnoses in Canada.
According to recent statistics, gastrointestinal cancers are diagnosed in over 30,000 Canadians each year. Colorectal cancer alone accounts for approximately 26,000 of these cases, making it one of the most commonly diagnosed cancers in the country. Pancreatic cancer, known for its aggressive nature and low survival rates, affects about 6,000 Canadians annually. Stomach, liver, and esophageal cancers also contribute to the overall burden, with thousands of new cases diagnosed each year.
The research initiatives supported by this funding will include clinical trials, biomarker discovery, and studies into the genetic and environmental factors contributing to gastrointestinal cancers.
"We applaud Princess Margaret Cancer Centre for making a meaningful impact to reduce the impact of cancer here in Canada and internationally. This new Research Chair can advance the understanding of gastrointestinal cancers and bring hope to patients and their families," added McCluskey.
About Alamos
Alamos is a Canadian-based intermediate gold producer with diversified production from three operations in North America. This includes the Young-Davidson mine and Island Gold District in northern Ontario, Canada, and the Mulatos District in Sonora State, Mexico. Additionally, the Company has a strong portfolio of growth projects, including the Phase 3+ Expansion at Island Gold, and the Lynn Lake project in Manitoba, Canada. Alamos employs more than 2,400 people and is committed to the highest standards of sustainable development. The Company’s shares are traded on the TSX and NYSE under the symbol “AGI”.
About The Princess Margaret Cancer Foundation
The Princess Margaret Cancer Foundation is Canada’s largest and leading cancer charity, dedicated to raising funds for Princess Margaret Cancer Centre, one of the world's top 5 cancer research centres known for its game-changing scientific achievements and exceptional patient treatment and care. Through philanthropy, events, our world-leading home lottery program, and commercialization initiatives, we make possible the critical funding required to accelerate cancer research, education, and clinical care -- benefitting patients at Princess Margaret Cancer Centre, throughout Canada and the world. www.thepmcf.ca
FOR FURTHER INFORMATION, PLEASE CONTACT:
Scott K. Parsons
Senior Vice President, Corporate Development & Investor Relations
(416) 368-9932 x 5439
Khalid Elhaj
Vice President, Business Development & Investor Relations
(416) 368-9932 x 5427
ir@alamosgold.com
Kenzie Broddy
Director, Communications
The Princess Margaret Cancer Foundation
437.215.6961
Kenzie.broddy@thepmcf.ca
The TSX and NYSE have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is the purpose of Alamos Gold's $2 million contribution to The Princess Margaret Cancer Foundation?
Who was named as the inaugural Alamos Gold Chair in Gastrointestinal Surgical Oncology?
What types of cancers will the Alamos Gold Chair (AGI) research focus on?
How many Canadians are diagnosed with gastrointestinal cancers annually?
